Lonza Debuts New Dry Powder Inhalation Capsule Portfolio

Life sciences firm Lonza debuted a new portfolio of Capsugel Zephyr dry powder inhalation (DPI) capsule solutions this month and introduced services to help drug makers customize inhaled pulmonary drugs they produce.   

“Capsule-based DPI technology is quickly becoming the preferred DPI drug delivery platform for pulmonary delivery. It provides drug stability advantages, encourages patient compliance, and is cost-effective to manufacturing with various dose carrying capacity,” said Stef Vanquickenborne, vice president of research and development at Lonza Pharma & Biotech, in a statement. “With more than 20 years of experience in manufacturing DPI-capsules, Lonza offers a uniquely customized portfolio of polymers to meet the growing need of inhalation DPA products for pulmonary drug delivery.”

Lonza’s new DPI capsule solutions feature greater end-to-end consistency and improved release performance compared to other DPI drug delivery platforms, according to the company. The company’s full-service inhalation drug delivery approach features specialized encapsulation technologies, particle engineering platforms ,and customized capsules 

“With the launch of the Capsugel Zephyr capsule portfolio, Lonza will offer full end-to-end solutions for capsule-based DPI products,” Fabio Invernizzi, vice president of global sales, Capsule Delivery Solutions at Lonza Pharma & Biotech, said in the release. “Our specialized capsule technology provides our customers with the right solution to deliver optimal product performance for the pulmonary route; a testament to how patient-centricity and customer focus are at the heart of Lonza’s healthcare continuum.”

Get information or register for Powder Show Toronto, June 4-6, 2019

For more news headlines, articles, and equipment reviews, visit our Equipment Zones